# Spero Therapeutics, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Spero Therapeutics, Inc.). ## Overview Spero Therapeutics, Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on developing novel treatments for rare diseases and multidrug-resistant bacterial infections. Its pipeline has included tebipenem HBr, SPR720, and SPR206, with development activities supported through collaborations and government funding arrangements. ## Products & services • Tebipenem HBr oral carbapenem for cUTI/pyelonephritis • SPR720 oral program for NTM pulmonary disease • SPR206 anti-infective program for resistant infections • Clinical development and regulatory advancement • Collaboration and license-based development partnerships - **Tebipenem HBr** (95%) — Oral broad-spectrum carbapenem candidate for complicated urinary tract infections and pyelonephritis. - **Collaboration revenue** (5%) — Revenue recognized under license and development agreements with partners such as GSK and Pfizer. - **SPR720** (0%) — Oral investigational therapy for nontuberculous mycobacterial pulmonary disease. - **SPR206** (0%) — Investigational anti-infective program for multidrug-resistant bacterial infections. - Tebipenem HBr oral carbapenem for cUTI/pyelonephritis - SPR720 oral program for NTM pulmonary disease - SPR206 anti-infective program for resistant infections - Clinical development and regulatory advancement - Collaboration and license-based development partnerships ## Customers Spero’s direct commercial customers are not yet established because it is still a clinical-stage company. Its economic counterparties are primarily pharmaceutical partners, government agencies, and future healthcare payors and hospitals that would influence adoption if a product is approved. - **Pharmaceutical collaboration partners** (primary) — Partners such as GSK and Pfizer support development programs and share in the economics of selected assets. - **Government funding agencies** (primary) — Agencies such as NIAID support preclinical and clinical development through awards and contracts. - **Hospitals and inpatient providers** (secondary) — Potential future buyers for tebipenem HBr if approved for inpatient or bundled-payment settings. - **Government and commercial payors** (secondary) — They determine coverage and reimbursement levels that affect future adoption and pricing. - **Infectious disease physicians** (secondary) — Prescribers who would use the company’s anti-infective products for resistant infections. - Pharmaceutical partners funding development through collaborations and licenses - Government agencies supporting clinical research and program development - Hospitals and inpatient providers for future anti-infective use cases - Government health programs and third-party payors for reimbursement - Physicians treating complicated infections and resistant pathogens ## Geography Spero is headquartered in the United States and conducts development activities through a U.S.-based biopharmaceutical platform. Its supply chain and manufacturing network rely on third-party contract manufacturers in Asia, including facilities in Taiwan, while commercialization and reimbursement considerations are relevant in the U.S. and abroad. - Headquartered in the United States - Clinical development and corporate functions are U.S.-based - Third-party contract manufacturers are based in Asia - Some manufacturing facilities are in Taiwan - Future commercialization would depend on U.S. and international reimbursement ## Strategy Spero’s strategy is centered on advancing tebipenem HBr through late-stage development and regulatory filing while preserving optionality for its earlier programs. The company also relies on collaborations, government awards, and licensing arrangements to fund development until product sales, if any, become available. - **Advance tebipenem HBr to approval pathway** (short-term) — This asset is the main value driver and the most advanced program in the pipeline. - **Maintain external funding sources** (short-term) — The company depends on non-product revenue until commercialization is possible. - **Preserve pipeline optionality** (medium-term) — Earlier-stage programs may still create value if a viable path forward is found. - Advance tebipenem HBr toward regulatory submission - Use collaborations to fund and de-risk development - Preserve optionality for SPR720 and SPR206 assets - Rely on government awards and licensing for funding - Build future commercialization capability only if needed ## Risks Spero is highly dependent on the success of a small number of development assets, especially tebipenem HBr and its GSK collaboration. Clinical, regulatory, reimbursement, manufacturing, and funding risks are all material because the company does not yet generate product sales. - **Concentration in tebipenem HBr and GSK collaboration** [high] — The business is substantially dependent on one late-stage program and one major partner. - **Clinical development failure** [high] — Drug candidates may not meet endpoints, show safety issues, or fail to gain approval. - **Reimbursement and pricing pressure** [medium] — Hospital bundled payments and payor controls can limit uptake and pricing power. - **Manufacturing and supply chain disruption** [high] — The company relies on a small number of third-party manufacturers and one raw-material supplier. - **Financing risk** [high] — The company expects to need external funding until product sales are established. - Heavy dependence on tebipenem HBr and the GSK partnership - Clinical trial or regulatory setbacks could eliminate key value - Reimbursement and hospital bundling may limit adoption - Supply chain reliance on third-party Asian manufacturers - Need for additional capital before product sales begin ## Accounting Spero’s reported revenue is driven mainly by collaboration accounting and government awards rather than product sales, so timing of service periods and milestone-related recognition matters. Investors should also watch estimates tied to lease assets, restructuring charges, stock-based compensation, and foreign currency effects, all of which can move reported results without reflecting product demand. - **Collaboration revenue recognition** — GSK and Pfizer agreements - **Grant revenue and government awards** — NIAID and other awards - **Lease accounting and impairment** — Reported operating expense and asset values - **Stock-based compensation** — Operating loss and dilution analysis - **Foreign currency remeasurement** — Other income (expense), net - Collaboration revenue timing under GSK and Pfizer agreements - Grant revenue recognition from government awards - Stock-based compensation in R&D and G&A expenses - Lease accounting and right-of-use asset impairment - Foreign currency gains and losses on cash and payables --- *Last updated: 2026-04-29T04:59:46.589204+00:00*